Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
53
STOK Quote, Financials, Valuation and Earnings
Last price:
$30.59
Seasonality move
:
10.28%
Day range:
$28.27 - $30.63
52-week range:
$5.35 - $38.69
Dividend yield:
0%
P/E ratio:
46.34x
P/S ratio:
8.68x
P/B ratio:
5.67x
Volume:
632K
Avg. volume:
892.9K
1-year change:
242.83%
Market cap:
$1.7B
Revenue:
$36.6M
EPS (TTM):
$0.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$4.6M | -$0.73 | -77.5% | -289.69% | $37.13 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -44.74% | $9.67 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.69 | -2.58% | 114.59% | $191.03 |
|
INSM
Insmed, Inc.
|
$210.7M | -$1.30 | 151.38% | -27.32% | $215.78 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$138.9M | -$0.08 | 36.52% | -85.85% | $105.90 |
|
PFE
Pfizer Inc.
|
$16.9B | $0.57 | 1.95% | 42.9% | $28.66 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$30.58 | $37.13 | $1.7B | 46.34x | $0.00 | 0% | 8.68x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.14 | $9.67 | $249.1M | -- | $0.00 | 0% | -- |
|
BIIB
Biogen, Inc.
|
$178.30 | $191.03 | $26.2B | 16.26x | $0.00 | 0% | 2.70x |
|
INSM
Insmed, Inc.
|
$163.72 | $215.78 | $34.9B | -- | $0.00 | 0% | 69.67x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$90.44 | $105.90 | $4.6B | -- | $0.00 | 0% | 9.76x |
|
PFE
Pfizer Inc.
|
$25.15 | $28.66 | $143B | 14.66x | $0.43 | 6.84% | 2.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.379 | 0.37% | 6.17x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.161 | 4.95% | 2.64x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.665 | 32.07% | 1.77x |
|
INSM
Insmed, Inc.
|
44.07% | 2.489 | 2.43% | 4.18x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.390 | 8.47% | 3.01x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Stoke Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns STOK or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of --. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About STOK or ALDX?
Stoke Therapeutics, Inc. has a consensus price target of $37.13, signalling upside risk potential of 21.4%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 133.49%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.9 0 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is STOK or ALDX More Risky?
Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.241%.
-
Which is a Better Dividend Stock STOK or ALDX?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or ALDX?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.34x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.68x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.8.68x 46.34x $10.6M -$38.3M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns STOK or BIIB?
Biogen, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 19%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About STOK or BIIB?
Stoke Therapeutics, Inc. has a consensus price target of $37.13, signalling upside risk potential of 21.4%. On the other hand Biogen, Inc. has an analysts' consensus of $191.03 which suggests that it could grow by 7.14%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.9 0 0 BIIBBiogen, Inc.14 18 1 -
Is STOK or BIIB More Risky?
Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.
-
Which is a Better Dividend Stock STOK or BIIB?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or BIIB?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.34x while Biogen, Inc.'s PE ratio is 16.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.68x versus 2.70x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.8.68x 46.34x $10.6M -$38.3M BIIBBiogen, Inc.2.70x 16.26x $2.5B $466.5M
-
Which has Higher Returns STOK or INSM?
Insmed, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -259.95%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About STOK or INSM?
Stoke Therapeutics, Inc. has a consensus price target of $37.13, signalling upside risk potential of 21.4%. On the other hand Insmed, Inc. has an analysts' consensus of $215.78 which suggests that it could grow by 31.8%. Given that Insmed, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.9 0 0 INSMInsmed, Inc.17 1 0 -
Is STOK or INSM More Risky?
Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.
-
Which is a Better Dividend Stock STOK or INSM?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or INSM?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.34x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.68x versus 69.67x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.8.68x 46.34x $10.6M -$38.3M INSMInsmed, Inc.69.67x -- $142.3M -$370M
-
Which has Higher Returns STOK or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 2.18%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M -
What do Analysts Say About STOK or MIRM?
Stoke Therapeutics, Inc. has a consensus price target of $37.13, signalling upside risk potential of 21.4%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $105.90 which suggests that it could grow by 17.09%. Given that Stoke Therapeutics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.9 0 0 MIRMMirum Pharmaceuticals, Inc.8 0 0 -
Is STOK or MIRM More Risky?
Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.567%.
-
Which is a Better Dividend Stock STOK or MIRM?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or MIRM?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.34x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.68x versus 9.76x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.8.68x 46.34x $10.6M -$38.3M MIRMMirum Pharmaceuticals, Inc.9.76x -- $133M $2.9M
-
Which has Higher Returns STOK or PFE?
Pfizer Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 21.32%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About STOK or PFE?
Stoke Therapeutics, Inc. has a consensus price target of $37.13, signalling upside risk potential of 21.4%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 13.95%. Given that Stoke Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.9 0 0 PFEPfizer Inc.7 15 1 -
Is STOK or PFE More Risky?
Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock STOK or PFE?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.84% to investors and pays a quarterly dividend of $0.43 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or PFE?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.34x while Pfizer Inc.'s PE ratio is 14.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.68x versus 2.29x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.8.68x 46.34x $10.6M -$38.3M PFEPfizer Inc.2.29x 14.66x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
49
RGC alert for Jan 14
Regencell Bioscience Holdings Ltd. [RGC] is down 25.71% over the past day.
Buy
89
TTMI alert for Jan 14
TTM Technologies, Inc. [TTMI] is up 19.75% over the past day.
Sell
49
MRNA alert for Jan 14
Moderna, Inc. [MRNA] is up 17.08% over the past day.
